Skip navigation

Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMalarz, Katarzyna-
dc.contributor.authorMularski, Jacek-
dc.contributor.authorPacholczyk, Marcin-
dc.contributor.authorMusioł, Robert-
dc.identifier.citationCancers, Nr 12 2020pl_PL
dc.description.abstractIsocitrate dehydrogenases constitute a class of enzymes that are crucial for cellular metabolism. The overexpression or mutation of isocitrate dehydrogenases are often found in leukemias, glioblastomas, lung cancers, and ductal pancreatic cancer among others. Mutation R132H, which changes the functionality of an enzyme to produce mutagenic 2-hydroxyglutarate instead of a normal product, is particularly important in this field. A series of inhibitors were described for these enzymes of which ivosidenib was the first to be approved for treating leukemia and bile duct cancers in 2018. Here, we investigated the polypharmacological landscape of the activity for known sulfamoyl derivatives that are inhibitors, which are selective towards IDH1 R132H. These compounds appeared to be effective inhibitors of several non-receptor kinases at a similar level as imatinib and axitinib. The antiproliferative activity of these compounds against a panel of cancer cells was tested and is explained based on the relative expression levels of the investigated proteins. The multitargeted activity of these compounds makes them valuable agents against a wide range of cancers, regardless of the status of IDH1.pl_PL
dc.rightsUznanie autorstwa 3.0 Polska*
dc.subjectisocitrate dehydrogenasepl_PL
dc.subjecttyrosine kinasepl_PL
dc.subjectIDH1 inhibitorpl_PL
dc.subjectABL kinasepl_PL
dc.subjectanticancer activitypl_PL
dc.titleThe Landscape of the Anti-Kinase Activity of the IDH1 Inhibitorspl_PL
Appears in Collections:Artykuły (WNŚiT)

Files in This Item:
File Description SizeFormat 
Malarz_The_Landscape.pdf1,82 MBAdobe PDFView/Open
Show simple item record

Uznanie Autorstwa 3.0 Polska Creative Commons License Creative Commons